北京地区人群心血管事件预测指标的横断面研究
|
摘要
背景：高敏心肌肌钙蛋白T (high-sensitivity cardiac troponin T, hsTnT)是预测心血管事件的重要指标。在胸痛人群中,低浓度的hsTnT水平即具有重要的诊断和预后价值。在社区人群中,hsTnT水平与心血管危险关系如何尚不清楚。动脉僵硬度是预测心血管事件的另一个有用指标。过氧化物酶体增殖物激活受体(peroxisome proliferator-activated receptor, PPAR)及过氧化物酶体增殖物激活受体γ协同子la (peroxisome proliferator-activated receptor-γcoactivator-1a, PPARγC1a)在血糖、血脂的代谢中发挥着重要作用。动脉僵硬度是否与PPAR、PPARγC1a基因内部分单核苷酸多态性(single nucleotide polymorphisms, SNPs)相关,至今仍是个谜。
方法：用hsTnT试剂盒检测1365位社区中老年人hsTnT水平。用Framingham冠心病(coronary heart disease, CHD)风险和总心血管病(cardiovascular disease, CVD)风险评分公式计算心血管危险评分。用一种新的方法从血凝块提取DNA后,用实时定量聚合酶链反应(polymerase chain reaction, PCR)、TaqMan探针法获得1374人PPARα、PPARδ、PPARγC1a基因的rs1053049、rs1800234和rs8192678等3个SNPs位点基因型。分析hsTnT水平和心血管危险的关系,分析传统心血管危险因素及SNPs位点与动脉僵硬度的关系。
结果：在这个中老年社区人群中有719人(占52.7%)能检测到hsTnT (> 3.0pg/ml),150人(占11.0%)hsTnT升高(≥14.0pg/ml)。多变量分析显示男性、血糖、脑钠尿肽前体及肾小球率过滤与hsTnT水平独立相关。调整混杂因素后,高CHD风险(10年风险≥20%)随hsTnT水平增高而增加[OR值(每增加自然对数转化后hsTnT水平—单位)=2.134；95% CI,1.309至3.480；P=0.002],高总CVD风险(10年风险>20% )也随hsTnT水平增高而增加[OR值=2.362；95% CI,1.583至3.524；P<0.001]。hsTnT增高组和中间组与hsTnT水平最低组相比,其心血管风险明显增高。同时发现年龄、高血压、糖尿病等因素是影响动脉僵硬度的主要因素,rs1053049, rs1800234和rs8192678等三个SNPs位点及其组成的单体型和动脉僵硬度未见明确关系。
结论：在这个社区人群中,hsTnT水平与心血管危险因素相关,也与预测的心血管风险相关。hsTnT水平检测可能有利于发现心血管事件高风险人员。本研究未发现PPAR、PPARγC1a基因的SNPs位点与动脉僵硬度相关。
Background:The levels of high-sensitivity cardiac troponin T (hsTnT) was useful predictor for cardiovascular events. It provided useful information in population with chest pain, even at levels well below the detection limits of previous assays. However, the association between the levels of hsTnT and the predicted cardiovascular risk remains unclear. The arterial stiffness was another useful predictor for cardiovascular events. The peroxisome proliferator-activated receptor (PPAR) and peroxisome proliferator-activated receptor-y coactivator-la (PPARγC1a) play an important role in the metabolic process of glucose and lipid. Whether single nucleotide polymorphisms (SNPs) of these gene accout for arterial stiffness, it was still unknown.
Methods:The hsTnT levels were measured from 1,365 community-based middle-aged to older adults. The association between cardiovascular risk factors and hsTnT level was examined. The association between hsTnT levels and predicted coronary heart disease (CHD) risk and predicted general cardiovascular disease (CVD) risk were analyzed. After purification of genomic DNA samples from clotted blood by a new method, three valid SNPs, including rs1053049, rs1800234 and rs8192678 in the PPAR and PPARyCla gene were genotyped in 1,374 subjects (530 patients and 844 controls) by TaqMan allelic discrimination assays. The association between cardiovascular risk factors and SNPs with the arterial stiffness were analyzed.
Results:The detectable and elevated hsTnT levels were obtained in 719 subjects (52.7%) and 150 subjects (11.0%), respectively. In multivariable analyses, independent associations were found between hsTnT level and male sex, fasting glucose, N-terminal pro B-type natriuretic peptide, and estimated glomerular filtration rate. After adjustment for confounding factors, strong and graded increases in high predicted CHD risk (10-year risk≥20%) (adjusted OR per unit increase in the natural logarithm of the hsTnT levels,2.134; 95% CI,1.309 to 3.480; P=0.002) and high predicted general CVD risk (10-year risk>20%) (adjusted OR,2.362; 95% CI,1.583 to 3.524; P<0.001) were found. The higher predicted cardiovascular risk were found in intermediate and high hsTnT groups too. DNA samples purified from clotted blood were successfully performed through polymerase chain reaction, real time polymerase chain reaction, and melt curve analysis. Age, hypertension and diabetes mellitus were the main factors for increased arterial stiffness. There were no association between SNPs of rs1053049, rs1800234 and rs8192678 and the increased arterial stiffness among this community-based population. Haplotypes were analysed with multiple loci and there were no association between haplotypes and the increased arterial stiffness too.
Conclusions:The hsTnT levels were associated with several cardiovascular risk factors in this community-based population, and it coincided with predicted cardiovascular risk. Determining hsTnT levels may aid clinicians in identifying patients with increased cardiovascular risk in the general population. The present study did not find association between SNPs of PPAR and PPARγC1a with the increased arterial stiffness in this community-based population.
方法：用hsTnT试剂盒检测1365位社区中老年人hsTnT水平。用Framingham冠心病(coronary heart disease, CHD)风险和总心血管病(cardiovascular disease, CVD)风险评分公式计算心血管危险评分。用一种新的方法从血凝块提取DNA后,用实时定量聚合酶链反应(polymerase chain reaction, PCR)、TaqMan探针法获得1374人PPARα、PPARδ、PPARγC1a基因的rs1053049、rs1800234和rs8192678等3个SNPs位点基因型。分析hsTnT水平和心血管危险的关系,分析传统心血管危险因素及SNPs位点与动脉僵硬度的关系。
结果：在这个中老年社区人群中有719人(占52.7%)能检测到hsTnT (> 3.0pg/ml),150人(占11.0%)hsTnT升高(≥14.0pg/ml)。多变量分析显示男性、血糖、脑钠尿肽前体及肾小球率过滤与hsTnT水平独立相关。调整混杂因素后,高CHD风险(10年风险≥20%)随hsTnT水平增高而增加[OR值(每增加自然对数转化后hsTnT水平—单位)=2.134；95% CI,1.309至3.480；P=0.002],高总CVD风险(10年风险>20% )也随hsTnT水平增高而增加[OR值=2.362；95% CI,1.583至3.524；P<0.001]。hsTnT增高组和中间组与hsTnT水平最低组相比,其心血管风险明显增高。同时发现年龄、高血压、糖尿病等因素是影响动脉僵硬度的主要因素,rs1053049, rs1800234和rs8192678等三个SNPs位点及其组成的单体型和动脉僵硬度未见明确关系。
结论：在这个社区人群中,hsTnT水平与心血管危险因素相关,也与预测的心血管风险相关。hsTnT水平检测可能有利于发现心血管事件高风险人员。本研究未发现PPAR、PPARγC1a基因的SNPs位点与动脉僵硬度相关。
Background:The levels of high-sensitivity cardiac troponin T (hsTnT) was useful predictor for cardiovascular events. It provided useful information in population with chest pain, even at levels well below the detection limits of previous assays. However, the association between the levels of hsTnT and the predicted cardiovascular risk remains unclear. The arterial stiffness was another useful predictor for cardiovascular events. The peroxisome proliferator-activated receptor (PPAR) and peroxisome proliferator-activated receptor-y coactivator-la (PPARγC1a) play an important role in the metabolic process of glucose and lipid. Whether single nucleotide polymorphisms (SNPs) of these gene accout for arterial stiffness, it was still unknown.
Methods:The hsTnT levels were measured from 1,365 community-based middle-aged to older adults. The association between cardiovascular risk factors and hsTnT level was examined. The association between hsTnT levels and predicted coronary heart disease (CHD) risk and predicted general cardiovascular disease (CVD) risk were analyzed. After purification of genomic DNA samples from clotted blood by a new method, three valid SNPs, including rs1053049, rs1800234 and rs8192678 in the PPAR and PPARyCla gene were genotyped in 1,374 subjects (530 patients and 844 controls) by TaqMan allelic discrimination assays. The association between cardiovascular risk factors and SNPs with the arterial stiffness were analyzed.
Results:The detectable and elevated hsTnT levels were obtained in 719 subjects (52.7%) and 150 subjects (11.0%), respectively. In multivariable analyses, independent associations were found between hsTnT level and male sex, fasting glucose, N-terminal pro B-type natriuretic peptide, and estimated glomerular filtration rate. After adjustment for confounding factors, strong and graded increases in high predicted CHD risk (10-year risk≥20%) (adjusted OR per unit increase in the natural logarithm of the hsTnT levels,2.134; 95% CI,1.309 to 3.480; P=0.002) and high predicted general CVD risk (10-year risk>20%) (adjusted OR,2.362; 95% CI,1.583 to 3.524; P<0.001) were found. The higher predicted cardiovascular risk were found in intermediate and high hsTnT groups too. DNA samples purified from clotted blood were successfully performed through polymerase chain reaction, real time polymerase chain reaction, and melt curve analysis. Age, hypertension and diabetes mellitus were the main factors for increased arterial stiffness. There were no association between SNPs of rs1053049, rs1800234 and rs8192678 and the increased arterial stiffness among this community-based population. Haplotypes were analysed with multiple loci and there were no association between haplotypes and the increased arterial stiffness too.
Conclusions:The hsTnT levels were associated with several cardiovascular risk factors in this community-based population, and it coincided with predicted cardiovascular risk. Determining hsTnT levels may aid clinicians in identifying patients with increased cardiovascular risk in the general population. The present study did not find association between SNPs of PPAR and PPARγC1a with the increased arterial stiffness in this community-based population.
引文
1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics--2010 update:a report from the American Heart Association. Circulation 2010;121:e46-e215.
2. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
3. Cohn JN, Duprez DA, Grandits GA. Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment. Hypertension 2005;46:217-20.
4. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16.
5. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-95.
6. Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines:Analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007;115:e352-5.
7. Mingels A, Jacobs L, Michielsen E, Swaanenburg J, Wodzig W, van Dieijen-Visser M. Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem 2009;55:101-8.
8. Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009;361:2538-47.
9. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-67.
10. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009;361:868-77.
11. Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007;116:1242-9.
12. Peacock WFt, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008;358:2117-26.
13. Januzzi JL, Jr., Bamberg F, Lee H, et al. High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation 2010;121:1227-34.
14. Pham MX, Whooley MA, Evans GT, Jr., et al. Prognostic value of low-level cardiac troponin-I elevations in patients without definite acute coronary syndromes. Am Heart J 2004;148:776-82.
15. Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults:results from the Rancho Bernardo Study. J Am Coll Cardiol 2008;52:450-9.
16. Yamashina A, Tomiyama H, Arai T, et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003;26:615-22.
17. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-41.
18. Cohn JN. Arterial stiffness, vascular disease, and risk of cardiovascular events. Circulation 2006;113:601-3.
19. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness:methodological issues and clinical applications. Eur Heart J 2006;27:2588-605.
20. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients:a longitudinal study. Hypertension 2002;39:10-5.
21. Sutton-Tyrrell K, Najjar SS, Boudreau RM, et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005;111:3384-90.
22. Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke:the Rotterdam Study. Circulation 2006;113:657-63.
23. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113:664-70.
24. Mancia G, De Backer G, Dominiczak A, et al.2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536.
25. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension 2005;45:1050-5.
26. Rosenzweig A. Scanning the genome for coronary risk. N Engl J Med 2007;357:497-9.
27. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007;316:1488-91.
28. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007;316:1491-3.
29. Lacolley P, Challande P, Osborne-Pellegrin M, Regnault V. Genetics and pathophysiology of arterial stiffness. Cardiovasc Res 2009;81:637-48.
30. Twerenbold R, Reichlin T, Mueller C. Clinical application of sensitive cardiac troponin assays:potential and limitations. Biomark Med 2010;4:395-401.
31. Antman EM. Decision making with cardiac troponin tests. N Engl J Med 2002;346:2079-82.
32. Bleier J, Vorderwinkler KP, Falkensammer J, et al. Different intracellular compartmentations of cardiac troponins and myosin heavy chains:a causal connection to their different early release after myocardial damage. Clin Chem 1998;44:1912-8.
33. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997;337:1648-53.
34. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
35. Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006; 113:1958-65.
36. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome:a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-5.
37. Zhang L, Zuo L, Xu G, et al. Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant 2007;22:1093-9.
38. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937-44.
39. Ford ES, Giles WH, Mokdad AH. The distribution of 10-Year risk for coronary heart disease among US adults:findings from the National Health and Nutrition Examination Survey Ⅲ. J Am Coll Cardiol 2004;43:1791-6.
40. D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care:the Framingham Heart Study. Circulation 2008;117:743-53.
41. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304:2494-502.
42. deFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL. Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol 2010;55:441-50.
43. Shave R, Baggish A, George K, et al. Exercise-induced cardiac troponin elevation:evidence, mechanisms, and implications. J Am Coll Cardiol 2010;56:169-76.
44. Kelley WE, Januzzi JL, Christenson RH. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin Chem 2009;55:2098-112.
45. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003;41:1387-93.
46. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-41.
47. Laufer EM, Mingels AM, Winkens MH, et al. The extent of coronary atherosclerosis is associated with increasing circulating levels of high sensitive cardiac troponin T. Arterioscler Thromb Vasc Biol 2010;30:1269-75.
48. Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115:1528-36.
49. Kurz K, Giannitsis E, Zehelein J, Katus HA. Highly sensitive cardiac troponin T values remain constant after brief exercise- or pharmacologic-induced reversible myocardial ischemia. Clin Chem 2008;54:1234-8.
50. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
51. Otsuka T, Kawada T, Ibuki C, Seino Y. Association between high-sensitivity cardiac troponin T levels and the predicted cardiovascular risk in middle-aged men without overt cardiovascular disease. Am Heart J 2010;159:972-8.
52. Chue CD, Townend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease:causes and consequences. Heart 2010;96:817-23.
53. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness:a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318-27.
54. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study):case-control study. Lancet 2004;364:937-52.
55. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study):a case-control study. Lancet 2008;372:224-33.
56. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension:a systematic review. Hypertension 2009;54:1328-36.
57. Henskens LH, Kroon AA, van Oostenbrugge RJ, et al. Increased aortic pulse wave velocity is associated with silent cerebral small-vessel disease in hypertensive patients. Hypertension 2008;52:1120-6.
58. van Popele NM, Grobbee DE, Bots ML, et al. Association between arterial stiffness and atherosclerosis:the Rotterdam Study. Stroke 2001;32:454-60.
59. McEniery CM, Wallace S, Mackenzie IS, et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006;48:602-8.
60. Tomiyama H, Hashimoto H, Tanaka H, et al. Continuous smoking and progression of arterial stiffening:a prospective study. J Am Coll Cardiol 2010;55:1979-87.
61. Mattace-Raso FU, van der Cammen TJ, van der Meer IM, et al. C-reactive protein and arterial stiffness in older adults:the Rotterdam Study. Atherosclerosis 2004;176:111-6.
62. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease:pathophysiology, clinical consequences, and medical therapy:Part Ⅰ. Circulation 2003;108:1527-32.
63. Schnabel R, Larson MG, Dupuis J, et al. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension 2008;51:1651-7.
64. Mitchell GF, DeStefano AL, Larson MG, et al. Heritability and a genome-wide linkage scan for arterial stiffness, wave reflection, and mean arterial pressure:the Framingham Heart Study. Circulation 2005; 112:194-9.
65. Gates PE, Tanaka H, Hiatt WR, Seals DR. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension 2004;44:35-41.
66. Brunner-La Rocca HP. Towards applicability of measures of arterial stiffness in clinical routine. Eur Heart J 2010;31:2320-2.
67. Martens FM, van der Graaf Y, Dijk JM, Olijhoek JK, Visseren FL. Carotid arterial stiffness is marginally higher in the metabolic syndrome and markedly higher in type 2 diabetes mellitus in patients with manifestations of arterial disease. Atherosclerosis 2008;197:646-53.
68. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
69. Vlachopoulos C, Dima I, Aznaouridis K, et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005; 112:2193-200.
70. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004;24:969-74.
71. Kim JS, Kang TS, Kim JB, et al. Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis 2007; 192:401-6.
72. Ruan L, Chen W, Srinivasan SR, et al. Relation of plasma homocysteine to arterial stiffness in black and white young adults (from the Bogalusa Heart Study). Am J Cardiol 2009; 103:985-8.
73. Homocysteine and risk of ischemic heart disease and stroke:a meta-analysis. JAMA 2002;288:2015-22.
74. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
75. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke:evidence on a causal link from mendelian randomisation. Lancet 2005;365:224-32.
76. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-9.
77. Colgan SM, Austin RC. Homocysteinylation of metallothionein impairs intracellular redox homeostasis:the enemy within! Arterioscler Thromb Vasc Biol 2007;27:8-11.
78. Weiss N, Keller C, Hoffmann U, Loscalzo J. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 2002;7:227-39.
79. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine:a link to atherosclerosis. Proc Natl Acad Sci U S A 1994;91:6369-73.
80. Charpiot P, Bescond A, Augier T, et al. Hyperhomocysteinemia induces elastolysis in minipig arteries:structural consequences, arterial site specificity and effect of captopril-hydrochlorothiazide. Matrix Biol 1998;17:559-74.
81. Postea O, Krotz F, Henger A, Keller C, Weiss N. Stereospecific and redox-sensitive increase in monocyte adhesion to endothelial cells by homocysteine. Arterioscler Thromb Vasc Biol 2006;26:508-13.
82. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
83. Ebbing M, Bleie O, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography:a randomized controlled trial. JAMA 2008;300:795-804.
84. Tousoulis D, Briasoulis A, Papageorgiou N, Antoniades C, Stefanadis C. Candidate gene polymorphisms and the 9p21 locus in acute coronary syndromes. Trends Mol Med 2008;14:441-9.
85. Morrison AC, Bare LA, Chambless LE, et al. Prediction of coronary heart disease risk using a genetic risk score:the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2007; 166:28-35.
86. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994;330:1041-6.
87. Lee DS, Pencina MJ, Benjamin EJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med 2006;355:138-47.
88. Adkins KK, Strom DA, Jacobson TE, Seemann CR, O'Brien DP, Heath EM. Utilizing genomic DNA purified from clotted blood samples for single nucleotide polymorphism genotyping. Arch Pathol Lab Med 2002;126:266-70.
89. Se Fum Wong S, Kuei JJ, Prasad N, et al. A simple method for DNA isolation from clotted blood extricated rapidly from serum separator tubes. Clin Chem 2007;53:522-4.
90. Everson RB, Mass MJ, Gallagher JE, Musser C, Dalzell J. Extraction of DNA from cryopreserved clotted human blood. Biotechniques 1993;15:18-20.
91. Siafakas N, Burnett L, Bennetts B, Proos A. Nonenzymatic extraction of DNA from blood collected into serum separator tubes. Clin Chem 1995;41:1045-6.
92. Garg UC, Hanson NQ, Tsai MY, Eckfeldt JH. Simple and rapid method for extraction of DNA from fresh and cryopreserved clotted human blood. Clin Chem 1996;42:647-8.
93. Salazar LA, Hirata MH, Cavalli SA, Machado MO, Hirata RD. Optimized procedure for DNA isolation from fresh and cryopreserved clotted human blood useful in clinical molecular testing. Clin Chem 1998;44:1748-50.
94. Kiechle FL, Zhang X. The postgenomic era:implications for the clinical laboratory. Arch Pathol Lab Med 2002;126:255-62.
95. Gemmell NJ, Akiyama S. An efficient method for the extraction of DNA from vertebrate tissues. Trends Genet 1996;12:338-9.
96. Chanock S. Candidate genes and single nucleotide polymorphisms (SNPs) in the study of human disease. Dis Markers 2001;17:89-98.
97. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006;116:571-80.
98. Flavell DM, Ireland H, Stephens JW, et al. Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes 2005;54:582-6.
99. Flavell DM, Jamshidi Y, Hawe E, et al. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002; 105:1440-5.
100. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS:testing haplotype effects in association studies. Bioinformatics 2007;23:1038-9.
101. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008;358:1240-9.
102. Naito H, Yamanoshita O, Kamijima M, et al. Association of V227A PPARalpha polymorphism with altered serum biochemistry and alcohol drinking in Japanese men. Pharmacogenet Genomics 2006; 16:569-77.
103. Liu MH, Li J, Shen P, Husna B, Tai ES, Yong EL. A natural polymorphism in peroxisome proliferator-activated receptor-alpha hinge region attenuates transcription due to defective release of nuclear receptor corepressor from chromatin. Mol Endocrinol 2008;22:1078-92.
104. Chan E, Tan CS, Deurenberg-Yap M, Chia KS, Chew SK, Tai ES. The V227A polymorphism at the PPARA locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women. Atherosclerosis 2006;187:309-15.
105. Tai ES, Demissie S, Cupples LA, et al. Association between the PPARA L162V polymorphism and plasma lipid levels:the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002;22:805-10.
106. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-26.
107. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-908.
108. Murabito JM, Pencina MJ, Nam BH, et al. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA 2005;294:3117-23.
109. Helgadottir A, Thorleifsson G, Magnusson KP, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008;40:217-24.
110.Palomaki GE, Melillo S, Bradley LA. Association between 9p21 genomic markers and heart disease:a meta-analysis. JAMA 2010;303:648-56.
111.Arnett DK, Baird AE, Barkley RA, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease:a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007;115:2878-901.
[1]Lopez AD, Murray CC. The global burden of disease,1990-2020. Nat Med 1998;4:1241-3.
[2]He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med 2005;353:1124-34.
[3]Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. Circulation 2000;102:1216-20.
[4]Antman EM. Decision making with cardiac troponin tests. N Engl J Med 2002;346:2079-82.
[5]Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53.
[6]Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996;335:1333-41.
[7]Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines:Analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007;115:e352-5.
[8]Mingels A, Jacobs L, Michielsen E, Swaanenburg J, Wodzig W, van Dieijen-Visser M. Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem 2009;55:101-8.
[9]Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-67.
[10]Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009;361:2538-47.
[11]Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons:endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304.
[12]Muller-Bardorff M, Hallermayer K, Schroder A, et al. Improved troponin T ELISA specific for cardiac troponin T isoform:assay development and analytical and clinical validation. Clin Chem 1997;43:458-66.
[13]Hallermayer K, Klenner D, Vogel R. Use of recombinant human cardiac Troponin T for standardization of third generation Troponin T methods. Scand J Clin Lab Invest Suppl 1999;230:128-31.
[14]Davis GK, Labugger R, Van Eyk JE, Apple FS. Cardiac troponin T is not detected in Western blots of diseased renal tissue. Clin Chem 2001;47:782-3.
[15]Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:254-61.
[16]Reiter M, Twerenbold R, Reichlin T, et al. Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. Eur Heart J 2011.
[17]Januzzi JL, Jr., Bamberg F, Lee H, et al. High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation 2010;121:1227-34.
[18]Welsford M. ACP Journal Club. Sensitive cardiac troponin assays were more accurate than a standard troponin assay for early diagnosis of AMI. Ann Intern Med 2009;151:JC6-12.
[19]Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007;116:1242-9.
[20]Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2009;54:1715-21.
[21]Peacock WFt, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008;358:2117-26.
[22]deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304:2494-502.
[23]de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010;304:2503-12.
[24]Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006; 113:1958-65.
[25]Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the atherosclerosis risk in communities study. Circulation 2011;123:1367-76.
[26]Hickman PE, Potter JM, Aroney C, et al. Cardiac troponin may be released by ischemia alone, without necrosis. Clin Chim Acta 2010;411:318-23.
[27]Jeremias A, Gibson CM. Narrative review:alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med 2005;142:786-91.
[28]Kelley WE, Januzzi JL, Christenson RH. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin Chem 2009;55:2098-112.
[29]Inbar R, Shoenfeld Y. Elevated cardiac troponins:the ultimate marker for myocardial necrosis, but not without a differential diagnosis. Isr Med Assoc J 2009;11:50-3.
[30]Shave R, Baggish A, George K, et al. Exercise-induced cardiac troponin elevation:evidence, mechanisms, and implications. J Am Coll Cardiol 2010;56:169-76.
[31]Eggers KM, Lind L, Venge P, Lindahl B. Will the universal definition of myocardial infarction criteria result in an overdiagnosis of myocardial infarction? Am J Cardiol 2009;103:588-91.
1 Armitage J.The safety of statins in clinical practice.Lancet,2007;370:1781～1790
2 Baigent C,Keech A,Keamey PM,et al.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.Lancet,2005;366:1267～1278
3 Kearney PM,Blackwell L,Collins R,et al.Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins:a meta-analysis.Lancet,2008;371:117～125
4 Ridker PM,Danielson E,Fonseca FA,et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med,2008;359:2195～2207
5 LaRosa JC,Grundy SM,Waters DD,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med,2005;352:1425～1435
6 Pedersen TR,Faergeman O,Kastelein JJ,et al.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction:the IDEAL study:a randomized controlled trial JAMA,2005;294:2437～2445
7 Yusuf S,Lonn E,Bosch J.Lipid lowering for primary prevention.Lancet,2009;373:1152～1155
8 Freeman DJ,Norrie J,Sattar N,et al.Pravastatin and the development of diabetes mellitus:evidence for a protective treatment effect in the West of Scotland Coronary Prevention study.Circulation,2001;103:357～362
9 Keech A,Colquhoun D,Best J,et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose:results from the LIPID trial.Diabetes Care,2003;26:2713～2721
10 Sever PS,Dahlof B,Poulter NR,et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations,in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomised controlled trial.Lancet,2003;361:1149～1158
11 Collins R,Armitage J,Parish S,et al.MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5 963 people with diabetes:a randomised placebo-controlled trial.Lancet,2003;361:2005～2016
12 Kjekshus J,Apetrei E,Barrios V,et al.Rosuvastatin in older patients with systolic heart failure.N Engl J Med,2007;357:2248～2261
13 Sattar N,Preiss D,Murray HM,et al.Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials.Lancet,2010;375:735～742
14 Nakata M,Nagasaka S,Kusaka I,et al.Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLS2A4):implications in glycaemic control.Diabetologia,2006;49:1881～1892
15 Cannon CP.Balancing the benefits of statins versus a new risk-diabetes.Lancet,2010;375:700～701
16 Shepherd J,Barter P,Carmena R,et al.Effect of lowering ldl cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes:the treating to new targets (TNT) study.Diabetes Care,2006;29:1220～1226
17中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南.中华心血管病杂志,2007；35：390～413
2. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
3. Cohn JN, Duprez DA, Grandits GA. Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment. Hypertension 2005;46:217-20.
4. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16.
5. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-95.
6. Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines:Analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007;115:e352-5.
7. Mingels A, Jacobs L, Michielsen E, Swaanenburg J, Wodzig W, van Dieijen-Visser M. Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem 2009;55:101-8.
8. Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009;361:2538-47.
9. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-67.
10. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009;361:868-77.
11. Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007;116:1242-9.
12. Peacock WFt, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008;358:2117-26.
13. Januzzi JL, Jr., Bamberg F, Lee H, et al. High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation 2010;121:1227-34.
14. Pham MX, Whooley MA, Evans GT, Jr., et al. Prognostic value of low-level cardiac troponin-I elevations in patients without definite acute coronary syndromes. Am Heart J 2004;148:776-82.
15. Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults:results from the Rancho Bernardo Study. J Am Coll Cardiol 2008;52:450-9.
16. Yamashina A, Tomiyama H, Arai T, et al. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003;26:615-22.
17. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-41.
18. Cohn JN. Arterial stiffness, vascular disease, and risk of cardiovascular events. Circulation 2006;113:601-3.
19. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness:methodological issues and clinical applications. Eur Heart J 2006;27:2588-605.
20. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients:a longitudinal study. Hypertension 2002;39:10-5.
21. Sutton-Tyrrell K, Najjar SS, Boudreau RM, et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005;111:3384-90.
22. Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke:the Rotterdam Study. Circulation 2006;113:657-63.
23. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113:664-70.
24. Mancia G, De Backer G, Dominiczak A, et al.2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536.
25. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension 2005;45:1050-5.
26. Rosenzweig A. Scanning the genome for coronary risk. N Engl J Med 2007;357:497-9.
27. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007;316:1488-91.
28. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007;316:1491-3.
29. Lacolley P, Challande P, Osborne-Pellegrin M, Regnault V. Genetics and pathophysiology of arterial stiffness. Cardiovasc Res 2009;81:637-48.
30. Twerenbold R, Reichlin T, Mueller C. Clinical application of sensitive cardiac troponin assays:potential and limitations. Biomark Med 2010;4:395-401.
31. Antman EM. Decision making with cardiac troponin tests. N Engl J Med 2002;346:2079-82.
32. Bleier J, Vorderwinkler KP, Falkensammer J, et al. Different intracellular compartmentations of cardiac troponins and myosin heavy chains:a causal connection to their different early release after myocardial damage. Clin Chem 1998;44:1912-8.
33. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997;337:1648-53.
34. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
35. Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006; 113:1958-65.
36. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome:a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-5.
37. Zhang L, Zuo L, Xu G, et al. Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant 2007;22:1093-9.
38. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937-44.
39. Ford ES, Giles WH, Mokdad AH. The distribution of 10-Year risk for coronary heart disease among US adults:findings from the National Health and Nutrition Examination Survey Ⅲ. J Am Coll Cardiol 2004;43:1791-6.
40. D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care:the Framingham Heart Study. Circulation 2008;117:743-53.
41. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304:2494-502.
42. deFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL. Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol 2010;55:441-50.
43. Shave R, Baggish A, George K, et al. Exercise-induced cardiac troponin elevation:evidence, mechanisms, and implications. J Am Coll Cardiol 2010;56:169-76.
44. Kelley WE, Januzzi JL, Christenson RH. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin Chem 2009;55:2098-112.
45. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003;41:1387-93.
46. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997;336:1131-41.
47. Laufer EM, Mingels AM, Winkens MH, et al. The extent of coronary atherosclerosis is associated with increasing circulating levels of high sensitive cardiac troponin T. Arterioscler Thromb Vasc Biol 2010;30:1269-75.
48. Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007; 115:1528-36.
49. Kurz K, Giannitsis E, Zehelein J, Katus HA. Highly sensitive cardiac troponin T values remain constant after brief exercise- or pharmacologic-induced reversible myocardial ischemia. Clin Chem 2008;54:1234-8.
50. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
51. Otsuka T, Kawada T, Ibuki C, Seino Y. Association between high-sensitivity cardiac troponin T levels and the predicted cardiovascular risk in middle-aged men without overt cardiovascular disease. Am Heart J 2010;159:972-8.
52. Chue CD, Townend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic kidney disease:causes and consequences. Heart 2010;96:817-23.
53. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness:a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318-27.
54. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study):case-control study. Lancet 2004;364:937-52.
55. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study):a case-control study. Lancet 2008;372:224-33.
56. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension:a systematic review. Hypertension 2009;54:1328-36.
57. Henskens LH, Kroon AA, van Oostenbrugge RJ, et al. Increased aortic pulse wave velocity is associated with silent cerebral small-vessel disease in hypertensive patients. Hypertension 2008;52:1120-6.
58. van Popele NM, Grobbee DE, Bots ML, et al. Association between arterial stiffness and atherosclerosis:the Rotterdam Study. Stroke 2001;32:454-60.
59. McEniery CM, Wallace S, Mackenzie IS, et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006;48:602-8.
60. Tomiyama H, Hashimoto H, Tanaka H, et al. Continuous smoking and progression of arterial stiffening:a prospective study. J Am Coll Cardiol 2010;55:1979-87.
61. Mattace-Raso FU, van der Cammen TJ, van der Meer IM, et al. C-reactive protein and arterial stiffness in older adults:the Rotterdam Study. Atherosclerosis 2004;176:111-6.
62. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease:pathophysiology, clinical consequences, and medical therapy:Part Ⅰ. Circulation 2003;108:1527-32.
63. Schnabel R, Larson MG, Dupuis J, et al. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension 2008;51:1651-7.
64. Mitchell GF, DeStefano AL, Larson MG, et al. Heritability and a genome-wide linkage scan for arterial stiffness, wave reflection, and mean arterial pressure:the Framingham Heart Study. Circulation 2005; 112:194-9.
65. Gates PE, Tanaka H, Hiatt WR, Seals DR. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension 2004;44:35-41.
66. Brunner-La Rocca HP. Towards applicability of measures of arterial stiffness in clinical routine. Eur Heart J 2010;31:2320-2.
67. Martens FM, van der Graaf Y, Dijk JM, Olijhoek JK, Visseren FL. Carotid arterial stiffness is marginally higher in the metabolic syndrome and markedly higher in type 2 diabetes mellitus in patients with manifestations of arterial disease. Atherosclerosis 2008;197:646-53.
68. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
69. Vlachopoulos C, Dima I, Aznaouridis K, et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005; 112:2193-200.
70. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004;24:969-74.
71. Kim JS, Kang TS, Kim JB, et al. Significant association of C-reactive protein with arterial stiffness in treated non-diabetic hypertensive patients. Atherosclerosis 2007; 192:401-6.
72. Ruan L, Chen W, Srinivasan SR, et al. Relation of plasma homocysteine to arterial stiffness in black and white young adults (from the Bogalusa Heart Study). Am J Cardiol 2009; 103:985-8.
73. Homocysteine and risk of ischemic heart disease and stroke:a meta-analysis. JAMA 2002;288:2015-22.
74. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
75. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke:evidence on a causal link from mendelian randomisation. Lancet 2005;365:224-32.
76. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-9.
77. Colgan SM, Austin RC. Homocysteinylation of metallothionein impairs intracellular redox homeostasis:the enemy within! Arterioscler Thromb Vasc Biol 2007;27:8-11.
78. Weiss N, Keller C, Hoffmann U, Loscalzo J. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med 2002;7:227-39.
79. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine:a link to atherosclerosis. Proc Natl Acad Sci U S A 1994;91:6369-73.
80. Charpiot P, Bescond A, Augier T, et al. Hyperhomocysteinemia induces elastolysis in minipig arteries:structural consequences, arterial site specificity and effect of captopril-hydrochlorothiazide. Matrix Biol 1998;17:559-74.
81. Postea O, Krotz F, Henger A, Keller C, Weiss N. Stereospecific and redox-sensitive increase in monocyte adhesion to endothelial cells by homocysteine. Arterioscler Thromb Vasc Biol 2006;26:508-13.
82. Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
83. Ebbing M, Bleie O, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography:a randomized controlled trial. JAMA 2008;300:795-804.
84. Tousoulis D, Briasoulis A, Papageorgiou N, Antoniades C, Stefanadis C. Candidate gene polymorphisms and the 9p21 locus in acute coronary syndromes. Trends Mol Med 2008;14:441-9.
85. Morrison AC, Bare LA, Chambless LE, et al. Prediction of coronary heart disease risk using a genetic risk score:the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2007; 166:28-35.
86. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994;330:1041-6.
87. Lee DS, Pencina MJ, Benjamin EJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med 2006;355:138-47.
88. Adkins KK, Strom DA, Jacobson TE, Seemann CR, O'Brien DP, Heath EM. Utilizing genomic DNA purified from clotted blood samples for single nucleotide polymorphism genotyping. Arch Pathol Lab Med 2002;126:266-70.
89. Se Fum Wong S, Kuei JJ, Prasad N, et al. A simple method for DNA isolation from clotted blood extricated rapidly from serum separator tubes. Clin Chem 2007;53:522-4.
90. Everson RB, Mass MJ, Gallagher JE, Musser C, Dalzell J. Extraction of DNA from cryopreserved clotted human blood. Biotechniques 1993;15:18-20.
91. Siafakas N, Burnett L, Bennetts B, Proos A. Nonenzymatic extraction of DNA from blood collected into serum separator tubes. Clin Chem 1995;41:1045-6.
92. Garg UC, Hanson NQ, Tsai MY, Eckfeldt JH. Simple and rapid method for extraction of DNA from fresh and cryopreserved clotted human blood. Clin Chem 1996;42:647-8.
93. Salazar LA, Hirata MH, Cavalli SA, Machado MO, Hirata RD. Optimized procedure for DNA isolation from fresh and cryopreserved clotted human blood useful in clinical molecular testing. Clin Chem 1998;44:1748-50.
94. Kiechle FL, Zhang X. The postgenomic era:implications for the clinical laboratory. Arch Pathol Lab Med 2002;126:255-62.
95. Gemmell NJ, Akiyama S. An efficient method for the extraction of DNA from vertebrate tissues. Trends Genet 1996;12:338-9.
96. Chanock S. Candidate genes and single nucleotide polymorphisms (SNPs) in the study of human disease. Dis Markers 2001;17:89-98.
97. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006;116:571-80.
98. Flavell DM, Ireland H, Stephens JW, et al. Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes 2005;54:582-6.
99. Flavell DM, Jamshidi Y, Hawe E, et al. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002; 105:1440-5.
100. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS:testing haplotype effects in association studies. Bioinformatics 2007;23:1038-9.
101. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008;358:1240-9.
102. Naito H, Yamanoshita O, Kamijima M, et al. Association of V227A PPARalpha polymorphism with altered serum biochemistry and alcohol drinking in Japanese men. Pharmacogenet Genomics 2006; 16:569-77.
103. Liu MH, Li J, Shen P, Husna B, Tai ES, Yong EL. A natural polymorphism in peroxisome proliferator-activated receptor-alpha hinge region attenuates transcription due to defective release of nuclear receptor corepressor from chromatin. Mol Endocrinol 2008;22:1078-92.
104. Chan E, Tan CS, Deurenberg-Yap M, Chia KS, Chew SK, Tai ES. The V227A polymorphism at the PPARA locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women. Atherosclerosis 2006;187:309-15.
105. Tai ES, Demissie S, Cupples LA, et al. Association between the PPARA L162V polymorphism and plasma lipid levels:the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002;22:805-10.
106. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115-26.
107. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-908.
108. Murabito JM, Pencina MJ, Nam BH, et al. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. JAMA 2005;294:3117-23.
109. Helgadottir A, Thorleifsson G, Magnusson KP, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 2008;40:217-24.
110.Palomaki GE, Melillo S, Bradley LA. Association between 9p21 genomic markers and heart disease:a meta-analysis. JAMA 2010;303:648-56.
111.Arnett DK, Baird AE, Barkley RA, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease:a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007;115:2878-901.
[1]Lopez AD, Murray CC. The global burden of disease,1990-2020. Nat Med 1998;4:1241-3.
[2]He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med 2005;353:1124-34.
[3]Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. Circulation 2000;102:1216-20.
[4]Antman EM. Decision making with cardiac troponin tests. N Engl J Med 2002;346:2079-82.
[5]Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation 2007;116:2634-53.
[6]Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996;335:1333-41.
[7]Apple FS, Jesse RL, Newby LK, Wu AH, Christenson RH. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines:Analytical issues for biochemical markers of acute coronary syndromes. Circulation 2007;115:e352-5.
[8]Mingels A, Jacobs L, Michielsen E, Swaanenburg J, Wodzig W, van Dieijen-Visser M. Reference population and marathon runner sera assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and I assays. Clin Chem 2009;55:101-8.
[9]Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361:858-67.
[10]Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009;361:2538-47.
[11]Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons:endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304.
[12]Muller-Bardorff M, Hallermayer K, Schroder A, et al. Improved troponin T ELISA specific for cardiac troponin T isoform:assay development and analytical and clinical validation. Clin Chem 1997;43:458-66.
[13]Hallermayer K, Klenner D, Vogel R. Use of recombinant human cardiac Troponin T for standardization of third generation Troponin T methods. Scand J Clin Lab Invest Suppl 1999;230:128-31.
[14]Davis GK, Labugger R, Van Eyk JE, Apple FS. Cardiac troponin T is not detected in Western blots of diseased renal tissue. Clin Chem 2001;47:782-3.
[15]Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:254-61.
[16]Reiter M, Twerenbold R, Reichlin T, et al. Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. Eur Heart J 2011.
[17]Januzzi JL, Jr., Bamberg F, Lee H, et al. High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation 2010;121:1227-34.
[18]Welsford M. ACP Journal Club. Sensitive cardiac troponin assays were more accurate than a standard troponin assay for early diagnosis of AMI. Ann Intern Med 2009;151:JC6-12.
[19]Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007;116:1242-9.
[20]Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol 2009;54:1715-21.
[21]Peacock WFt, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008;358:2117-26.
[22]deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304:2494-502.
[23]de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010;304:2503-12.
[24]Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006; 113:1958-65.
[25]Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the atherosclerosis risk in communities study. Circulation 2011;123:1367-76.
[26]Hickman PE, Potter JM, Aroney C, et al. Cardiac troponin may be released by ischemia alone, without necrosis. Clin Chim Acta 2010;411:318-23.
[27]Jeremias A, Gibson CM. Narrative review:alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med 2005;142:786-91.
[28]Kelley WE, Januzzi JL, Christenson RH. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin Chem 2009;55:2098-112.
[29]Inbar R, Shoenfeld Y. Elevated cardiac troponins:the ultimate marker for myocardial necrosis, but not without a differential diagnosis. Isr Med Assoc J 2009;11:50-3.
[30]Shave R, Baggish A, George K, et al. Exercise-induced cardiac troponin elevation:evidence, mechanisms, and implications. J Am Coll Cardiol 2010;56:169-76.
[31]Eggers KM, Lind L, Venge P, Lindahl B. Will the universal definition of myocardial infarction criteria result in an overdiagnosis of myocardial infarction? Am J Cardiol 2009;103:588-91.
1 Armitage J.The safety of statins in clinical practice.Lancet,2007;370:1781～1790
2 Baigent C,Keech A,Keamey PM,et al.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.Lancet,2005;366:1267～1278
3 Kearney PM,Blackwell L,Collins R,et al.Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins:a meta-analysis.Lancet,2008;371:117～125
4 Ridker PM,Danielson E,Fonseca FA,et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med,2008;359:2195～2207
5 LaRosa JC,Grundy SM,Waters DD,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med,2005;352:1425～1435
6 Pedersen TR,Faergeman O,Kastelein JJ,et al.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction:the IDEAL study:a randomized controlled trial JAMA,2005;294:2437～2445
7 Yusuf S,Lonn E,Bosch J.Lipid lowering for primary prevention.Lancet,2009;373:1152～1155
8 Freeman DJ,Norrie J,Sattar N,et al.Pravastatin and the development of diabetes mellitus:evidence for a protective treatment effect in the West of Scotland Coronary Prevention study.Circulation,2001;103:357～362
9 Keech A,Colquhoun D,Best J,et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose:results from the LIPID trial.Diabetes Care,2003;26:2713～2721
10 Sever PS,Dahlof B,Poulter NR,et al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations,in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomised controlled trial.Lancet,2003;361:1149～1158
11 Collins R,Armitage J,Parish S,et al.MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5 963 people with diabetes:a randomised placebo-controlled trial.Lancet,2003;361:2005～2016
12 Kjekshus J,Apetrei E,Barrios V,et al.Rosuvastatin in older patients with systolic heart failure.N Engl J Med,2007;357:2248～2261
13 Sattar N,Preiss D,Murray HM,et al.Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials.Lancet,2010;375:735～742
14 Nakata M,Nagasaka S,Kusaka I,et al.Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLS2A4):implications in glycaemic control.Diabetologia,2006;49:1881～1892
15 Cannon CP.Balancing the benefits of statins versus a new risk-diabetes.Lancet,2010;375:700～701
16 Shepherd J,Barter P,Carmena R,et al.Effect of lowering ldl cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes:the treating to new targets (TNT) study.Diabetes Care,2006;29:1220～1226
17中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南.中华心血管病杂志,2007；35：390～413